miRNA-1236 Inhibits HIV-1 Infection of Monocytes by Repressing Translation of Cellular Factor VprBP

Li Ma1,2, Chan-Juan Shen2, Éric A. Cohen3, Si-Dong Xiong1, Jian-Hua Wang2*
1 Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology & Medical Sciences, Soochow University, Suzhou, China, 2 Key Laboratory of Molecular Virology & Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China, 3 Laboratory of Human Retrovirology, Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada

Abstract

Primary monocytes are refractory to HIV-1 infection and become permissive upon differentiation into monocyte-derived dendritic cells (MDDCs) or macrophages. Multiple mechanisms have been proposed to interpret HIV-1 restriction in monocytes. Human cellular miRNAs can modulate HIV-1 infection by targeting either conserved regions of the HIV-1 genome or host gene transcripts. We have recently reported that the translation of host protein pur-alpha is repressed by abundant cellular miRNAs to inhibit HIV-1 infection in monocytes. Here, we report that the transcript of another cellular factor, VprBP [Vpr (HIV-1)-binding protein], was repressed by cellular miRNA-1236, which contributes to HIV-1 restriction in monocytes. Transfection of miR-1236 inhibitors enhanced translation of VprBP in monocytes and significantly promoted viral infection; exogenous input of synthesized miR-1236 mimics into MDDCs suppressed translation of VprBP, and, accordingly, significantly impaired viral infection. Our data emphasize the role of miRNA in modulating differentiation-dependent susceptibility of the host cell to HIV-1 infection. Understanding the modulation of HIV-1 infection by cellular miRNAs may provide key small RNAs or the identification of new important protein targets regulated by miRNAs for the development of antiviral strategies.

Citation: Ma L, Shen C-J, Cohen ÉA, Xiong S-D, Wang J-H (2014) miRNA-1236 Inhibits HIV-1 Infection of Monocytes by Repressing Translation of Cellular Factor VprBP. PLoS ONE 9(6): e99535. doi:10.1371/journal.pone.0099535

Introduction

miRNAs are small non-coding RNA molecules (18–22 nucleotides) found in eukaryotic cells. miRNAs are vital post-transcriptional regulators, and the binding of miRNAs to the 3′-untranslated regions on target mRNA transcripts usually results in translational repression or target degradation [1]. aberrant expression of miRNAs has been implicated in development and progression of many infectious diseases including HIV-1 infection [2,3,4,5,6,7,8,9]. Higher serum levels of miR-122 have been recently reported as potential biomarkers for AIDS-related non-Hodgkin lymphoma [10], and disrupted expression of certain miRNAs by HIV-1 or simian immunodeficiency virus (SIV) infection in intestinal mucosa is related to epithelial homeostasis disturbance and intestinal enteropathy [11]. Meanwhile, host cellular miRNAs can modulate HIV-1 infection by targeting either the conserved regions of HIV-1 genome or host gene transcripts, and these miRNAs may play pivotal roles in maintaining viral latency and promoting host defense [12,13,14]. HIV-1 nef appears to be the most widely focused gene for studying binding with miRNAs. The highly expressed cellular miRNAs miR-125b, miR-150, miR-28, miR-223 and miR-382 repress HIV-1 replication by targeting nef 3′-long-terminal repeat (LTR) region and contribute to viral latency in resting CD4+ T lymphocytes [15]. miR-29a specifically targets HIV-1 nef transcription and reduces viral production and infectivity, enhances HIV-1 mRNA association with RNA-induced silencing complexes, and sequesters viral mRNA in P bodies for further degradation [16,17,18,19]. a cluster of other host miRNAs, such as miR-15a, miR-15b, miR-16, miR-224-3p, miR-223 and miR-24, have been studied in silico and predicted to bind with the HIV-1 nef 3′-LTR region [19]. Alternatively, some miRNAs regulate HIV-1 infection by targeting host gene transcripts. the differential regulation of cellular miR-148 on HLA-C alleles is associated with HIV control [20,21]. Conversely, certain host cellular miRNAs appear to be essential for HIV to establish infection. Cellular miR-132 is upregulated in activated CD4+ T cells and potentiates HIV-1 replication by targeting host factor McCP2 (Methyl-GpG binding protein 2) [22]. miR-217 and miR-34a are reported to favor Tat-induced HIV-1 LTR-driven transactivation by downregulating SIRT1 (sirtuin 1), a host-cell-encoded class II deacetylase [23,24]. Recently, a novel HIV-1-encoded miRNA miR-H3 was identified by computational
prediction and deep sequencing, miR-H3 is located in the mRNA region encoding the active center of reverse transcriptase and targets the HIV-1 5' -LTR for upregulating promoter activity and viral transcription [25]. Understanding these roles of miRNAs in HIV-1 replication will be helpful to elucidate host-mediated antiviral response and explore new antiviral strategies.

Primary monocytes are refractory to HIV-1 infection and become permissive upon differentiation into macrophages or dendritic cells (DCs) [26,27,28,29]. Multiple inefficiencies in several post-entry steps of the HIV-1 life cycle, such as reverse transcription, nuclear import of pre-integration complex, and viral translation, have been shown to be responsible for HIV-1 restriction in monocytes [29,30,31,32]. The post-entry restriction of HIV-1 may be due to the existence of potential restriction factors or the absence of virus-dependent host factors. Low abundance of thymidine phosphorylase that is associated with a limited stock of dTTP contributes to refractory HIV-1 reverse transcription [28], and enrichment of host restriction factors, such as APOBEC3G/F [apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G/F] [33] and SAMHD1 (SAM domain and HD domain-containing protein 1) [34,35,36,37], are associated with HIV-1 restriction in monocytes or myeloid cells. miRNAs have also been reported to modulate HIV-1 infection in monocytes [38,39,40]. The abundance of miRNA-198 can repress the expression of cyclin T-1, and inhibit viral transcription in primary monocytes [41].

To uncover the restriction of HIV-1 replication by miRNAs in undifferentiated monocytes, we analyzed the miRNA expression profile in monocytes by miRNA-chip array and compared it with that of their differentiated monocyte-derived DC (MDDC) counterparts. We have recently reported that the translation of host protein pur-alpha was repressed by cellular miRNAs to inhibit HIV-1 infection in monocytes [39]. Here, we report that another host factor, namely VprBP, could also be targeted by cellular miRNA to modulate monocyte/MDDC susceptibility to HIV-1 infection.

Results

VprBP expression is essential for promoting HIV-1 infection

We investigated the importance of host factor VprBP in HIV-1 infection. We exogenously expressed VprBP by transfecting pCMV-myc-VprBP into HEK293T cells. As expected, overexpression of VprBP, as detected by Western blotting, significantly enhanced the infection of HIV-luc-Vpr9/VSV-G in a dose-dependent manner (Figure 1A and B). Conversely, knocking down expression of VprBP in Magi/CCL5 cells with specific VprBP siRNA, as confirmed by Western blotting (Figure 1C), impaired the infection of HIV-luc-Vpr9/VSV-G (Figure 1D). VprBP appeared to promote HIV-1 PIC (Pre-integration Complex) post-nuclear import event, because the knocking-down of VprBP in Magi/CCL5 cells did not diminish the HIV-1 products of both late reverse transcripts (Late RT) and 2-LTR, and on the other hand, the overexpression of VprBP in 293T cells did not significantly enhance the products of both HIV-1 Late RT and 2-LTR (data not shown). These data demonstrate that VprBP expression is important for efficient HIV-1 infection.

VprBP enhances HIV-1 infection in MDDCs in the presence of Vpr

To demonstrate further the importance of VprBP expression in promoting HIV-1 infection, we investigated VprBP expression in MDDCs. VprBP showed adequate expression in MDDCs compared with monocytes, as detected at the protein level (Figure 2A). When VprBP expression in MDDCs was interfered by specific siRNA (Figure 2B), the infection of pseudotyped single-cycle infectious HIV-luc-Vpr9/VSV-G was significantly impaired, demonstrating the crucial role of VprBP for efficient HIV-1 infection in primary MDDCs (Figure 2C).

VprBP is believed to be tightly conjugated with Vpr for functioning, for example, HIV-1 Vpr or HIV-2/SIVsmm/mac Vpx can interact with VprBP and assemble with DDB1 (DNA damage-binding protein 1) to form an E3 ubiquitin ligase complex, which targets cellular substrates for proteasome-mediated degradation and G2 cell-cycle arrest [42,43,44]. To investigate the dependence of Vpr for VprBP-promoting HIV-1 infection, we used Vpr-deficient HIV-1. Enhanced HIV-1 replication was only observed in Vpr-containing viruses, and knocking-down of VprBP did not impair the infection of vpr-deficient replication-competent HIV-1/AD8 in MDDCs (Figure 2D). The results demonstrate that promotion of VprBP in HIV-1 infection is Vpr dependent, and these results also confirm the VprBP dependence of Vpr-promoted HIV-1 infection. These data demonstrate the importance of VprBP in HIV-1 infection in MDDCs and the dependence on Vpr of VprBP-promoted viral infection.

Cellular miR-1236 targets 3'-untranslated region (UTR) of VprBP mRNA for translation inhibition in monocytes

We demonstrated above that VprBP was not expressed in monocytes, as detected at the protein level (Figure 2A). To elucidate the underlying mechanism for repression of VprBP expression in primary monocytes, VprBP transcription was further assessed. Unexpectedly, monocytes expressed even higher levels of VprBP mRNA transcripts than did MDDCs (Figure 3A). This indicates post-transcriptional inhibition of VprBP expression in monocytes.

Considering the regulatory role of miRNA on translation, we compared the miRNA expression in monocytes and MDDCs by Agilent miRNA-chip array. Target prediction of miRNAs and alignment of miRNAs with target sequences were achieved using TargetScan. We found the 17–24 bases of VprBP 3'-UTR were targeted by hsa-miR-1236. Expression of miR-1236 was verified with Bulge-loop miRNA qRT-PCR Primer Sets. The expression was adjusted based on U6 small nuclear RNA transcription. miR-1236 expression was significantly enhanced in monocytes compared with MDDCs (Figure 3B).

To confirm the targeting of VprBP mRNA 3'-UTR by miRNA-1236, 3'-UTR fragments of VprBP mRNA that contained the conserved binding positions were cloned into pGL3C.M, and mutations were introduced at the conserved binding positions of VprBP 3'-UTR to reduce Watson-Crick base pairing with miRNAs (Figure 3C). Inhibition of transfected miRNA mimics on expression of pGL3C.M-containing 3'-UTR fragments of VprBP or mutants was quantified using a dual-luciferase reporter assay system, and the relative activity of firefly and Renilla luciferases was calculated. Transfection with miRNA mimics significantly inhibited expression of pGL3C.M/VprBP 3'-UTR, and the mutation of conserved binding positions abolished the inhibition mediated by miRNA mimics (Figure 3D). These data demonstrated that miR-1236 targets VprBP mRNA 3'-UTR for repression in monocytes.
VprBP-targeted miR-1236 modulates differentiation-dependent susceptibility of monocytes/MDDCs to HIV-1 infection

HIV-1 infection was restricted in primary monocytes, but this restriction could be partially relieved when monocytes were differentiated into DCs upon stimulation with cytokines granulocyte–macrophage colony-stimulating factor and interleukin-4, as confirmed in Figure 4A. Multiple causes have been provided to reveal the differentiation-dependent susceptibility of monocytes to HIV-1 infection [29,30,31,32,39].

Given the important role of VprBP in promoting HIV-1 infection and the regulation of VprBP translation by miR-1236, we were interested in whether miR-1236 modulated monocyte/MDDC susceptibility to HIV-1 infection. We transfected monocytes with chemically synthesized, single-stranded miRNA inhibitors. As shown in Figure 4B and C, the transfection of miR-1236 inhibitors enhanced the translation of VprBP in monocytes and significantly promoted the infection of HIV-Luc/VSV-G. Complementarily, when the chemically synthesized miR-1236 mimics were transfected into MDDCs, translation of VprBP was suppressed (Figure 4D), and infection of MDDCs by HIV-Luc/VSV-G was accordingly significantly diminished (Figure 4E). These data demonstrate that miR-1236-mediated regulation of VprBP expression modulates the differentiation-dependent susceptibility of monocytes/MDDCs to HIV-1 infection.

Discussion

HIV-1 depends on host-cell-encoded factors for completing its life cycle, and hundreds of HIV-1-dependent host genes for replication have been uncovered by uniformly conducted in HIV-1 non-natural biology target cells or cell lines [45,46,47]. By adopting more physiologically relevant primary cells, we screened gene expression in monocytes by mRNA and miRNA microarray analysis, and compared it with that in their differentiated MDDCs [39]. Our purpose was to define on a large scale the differently expressed genes that could modulate HIV-1 susceptibility in monocytes/MDDCs.

VprBP, also known as DCAF1 (DDB1–CUL4-associated factor 1), is a component that forms a CUL4–DDB1–VprBP/DCAF1 E3 ubiquitin protein ligase complex. As the Vpr binding protein, VprBP is tightly conjugated with Vpr for functioning [48,49]. Here, we demonstrated that VprBP and Vpr showed mutual dependence in promoting HIV-1 infection, although the detailed mechanisms need to be clarified.

VprBP functions as the substrate recognition module within CUL4–DDB1–VprBP/DCAF1 E3 ubiquitin protein ligase complex and bridges target proteins to DDB1. HIV-1 Vpr or HIV-2/SIVsmm/mac Vpx can interact with VprBP and assembles with DDB1 to form an E3 ubiquitin ligase complex, which targets cellular substrates for proteasome-mediated degradation and G2 cell-cycle arrest [42,43,44,50]. A recent study has reported that the direct interaction of HIV-1 Vpr with structure-specific endonuclease regulator SLX4 recruits VprBP and kinase-active PLK1, and enhances cleavage of DNA by SLX4-associated MUS81–EME1 endonucleases, resulting in G2/M arrest [51]. Moreover, the DDB1–Cul4–DCAF1/VprBP E3 ubiquitin ligase complex appears essential for HIV1 Vpr-mediated degradation of the uracil-DNA glycosylases 2 and SMUG1 (single-strand-selective monofunctional uracil-DNA glycosylase 1) [52]. It has been
reported that DCAF1/VprBP is recruited by HIV-2/SIVsmm/Vpx to hijack the CUL4–DDB1 E3 ubiquitin ligase complex for degradation of host-restrictive factor SAMHD1 [34,35,53], facilitating HIV-1 infection in myeloid cells. However, SAMHD1 shows comparable expression in monocytes compared with MDDCs, suggesting that VprBP-facilitated HIV-1 infection in MDDCs is not attributed to the SAMHD1 degradation induced by CUL4–DDB1–DCAF1/VprBP E3 ubiquitin protein ligase complex.

In our miRNA-chip analysis, we also found that other cellular miRNAs, such as miR-15a, miR-15b, miR-16, miR-93, miR-106b and miR-20a, can inhibit HIV-1 infection in monocytes, and Pur-alpha, a host-cell-encoded transcription factor required for enhancing Tat-derived viral transactivation, was targeted for repression in monocytes [39].

In summary, our results demonstrate that host factor VprBP was targeted by cellular miR-1236 to modulate monocyte/MDDC differentiation-dependent susceptibility to HIV-1 infection. miRNA-based therapies are being developed, and understanding the modulation of HIV-1 infection by cellular miRNAs may provide key small RNAs or the identification of new important protein targets regulated by miRNAs for antiviral therapeutic interventions.

Materials and Methods

Cell

Human peripheral blood mononuclear cells (PBMCs) from healthy donor were purchased from Blood Center of Shanghai (Shanghai, China), CD14+ monocytes were isolated from PBMCs by using CD14 antibody-coated magnetic beads (Miltenyi Biotec, Germany) as previously described [54]. Monocytes were differentiated into MDDCs by stimulation with 50 ng/ml of GM-CFS and IL-4 for 6 days. HEK293T cell line was kindly gifted by Dr. Li Wu (The Ohio State University, Columbus, OH, USA) and HeLa-cell-derived Magi/CCR5 cell line[39] was a gift from Dr. Paul Zhou (Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China).

Virus stock and infection assay

Single-cycle HIV-Luc/VSV-G was produced by calcium-phosphate-mediated co-transfection of HEK293T cells with the luciferase reporter HIV-1 proviral vector NL-Luc-E'R(Vpr'+) and an expression plasmid of vesicular stomatitis virus G (VSV-G) protein. Replication competent HIV-1-AD8 (R5 tropic) virus or Vpr deletion AD8 virus were obtained by transfecting HIV-1 vectors of pNLAD8 or pNLAD8-DVpr, respectively. Plasmids were kindly provided by Dr. Li Wu (The Ohio State University, Columbus, OH, USA). Harvested supernatants that contained viral particles were filtered and quantified with p24 gag ELISA. Cells were infected with HIV-1-Luc/VSVG (1 ng p24 gag) or replication competent HIV-1 (1 ng p24 gag) for 2 h, and after washing, cells were further cultured for 2 days (cell line) or 5 days (MDDCs and monocytes). Viral infection was detected by measuring the luciferase activity from the cell lysates or detecting the p24 gag level from the supernatant. Data are mean ± SD. Results are representative of three independent experiments. *P<0.05 and ***P<0.001, were considered significant difference in paired Student t test.

doi:10.1371/journal.pone.0099535.g002

Figure 2. VprBP enhances HIV-1 infection in MDDCs. (A) VprBP expression in MDDCs and monocytes was detected by Western blotting. (B–D) Effect of knocking down VprBP on HIV-1 infection of MDDCs. MDDCs were transfected with specific siRNA 1# and 2# or off-target siRNA, and knockdown of VprBP was confirmed by Western blotting at 48 h post-transfection (B); transfected MDDCs were infected by HIV-luc/VSV-G for an additional 5 days, and viral infection was detected by measuring luciferase activity; alternatively, (C) transfected cells were infected for an additional 5 days by wild-type or vpr-deficient replication-competent HIV-1/AD8, and viral replication was monitored by quantifying p24 gag in culture supernatant. Data are mean ± SD. Results are representative of three independent experiments. *P<0.05 and ***P<0.001, were considered significant difference in paired Student t test.

miR-1236 Modulates HIV-1 Infection in Monocytes

PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e99535
Transfection of plasmids, siRNA, miRNA inhibitor or mimics

Cells were transfected by Lipofectamine 2000 (Invitrogen) with plasmids of pCMV-myc/pCMV-myc-VprBP, or with specific duplex siRNA of VprBP or off-target control (GenePharma, Shanghai, China), or with miR-1236 inhibitor or mimics (GenePharma). Then cells were either collected to detect the condition of expression by Western blotting, or for viral infection as described above. The sequences of siRNA duplex, miRNA inhibitors and mimics were as follows: VprBP siRNA 1# 5'-GGCCCAGAUAACCGAAUATT-3', VprBP siRNA 2# 5'-GCGACUCAUUCUCCAAUATT-3'. Plasmid pCMV-myc-VprBP encoding full-length myc-tagged VprBP (also known as DCAF1) was described previously[50]. For Western blotting, the anti-myc monoclonal antibody (clone 19C2, Abmart, Shanghai, China) and rabbit polyclonal antibody against VprBP (Santa Cruz, America) were used.

miRNA and miRNA microarray

The mRNA and miRNA expression profiles during monocyte to DC differentiation were screened with Affymetrix U133 plus 2.0 array and Agilent miRNA expression array as described previously [39], respectively. Genes were analyzed further online with the functional annotation tool in DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious Diseases, U.S. National Institute of Health, Bethesda, MD, USA). Target prediction of miRNAs and the alignments of miRNAs with target sequences were done by using TargetScan (http://www.targetscan.org). The expression of miRNAs was verified with Bulge-loop miRNA qRT-PCR Primer Sets (RiboBio Corp, Guangzhou, China). The expression was adjusted based on U6 small nuclear RNA transcription, and relative miRNA expression of indicated controls was calculated. PCR was performed on the ABI 7900HT Real-Time PCR system (Applied Biosystems, Foster City, CA, USA).

Construct and luciferase report assay

VprBP 3’ UTR was amplified from the total RNA extracted from the HEK293 cell line. Binding sites of VprBP 3’ UTR for miR-1236 were synthesized as follows: 5’-CGGAGCCATCACCTGCTTG-GGAAGAGTTCTTGGCAGAGAGAGGGGACA-3’ (forward), 5’-GATCTTTGTCGCCCTC TTCTCTCTCGCAAGAACTCTCCTTCAAGCGAAGTGATGCTCGAGCT-3’ (reverse). And point mutations of conserved binding sites of VprBP 3’-UTR for miR-1236 were synthesized as follow: 5’-CGGAGCCATCACCTGCTTG-GGAAGAGTTCTTGGCAGAGAGAGGGGACA-3’ (forward), 5’-GATCTTTGTCGCCCTC TTCTCTCTCGCAAGAACTCTCCTTCAAGCGAAGTGATGCTCGAGCT-3’ (reverse).}

Figure 3. 3’-UTR of VprBP mRNA is targeted by miR-1236. (A) Relative level of VprBP mRNA in monocytes compared with MDDCs. Total cellular RNAs were extracted from cells and the VprBP mRNA was measured with SYBR green-based semi-quantified real-time (RT-) PCR and normalized with β-actin. (B) Sequences of miR-1236 and alignments with the conserved binding position of 3’-UTR of VprBP, and the relative expression of miR-1236 in monocytes compared with MDDCs was quantified with Bulge-loop miRNA RT-PCR. (C) Schematic diagram showing binding of miR-1236 on 3’-UTR of VprBP mRNA and the point mutation of conserved positions of target sequences. (D) Inhibition of miRNA mimics on the expression of pGL3CM containing the 3’-UTR fragment of VprBP mRNA or mutant within conserved binding position. Data are mean ± SD. Results are representative of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001, were considered significant difference in paired Student t test.

doi:10.1371/journal.pone.0099535.g003
mutation was constructed with Bgl II and Sac I. Plasmid pGL3CM was kindly gifted by Dr. Ke Lan (Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China).

A Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) was used to examine the effects of miRNAs on their target genes as described previously[39]. Briefly, pGL3CM reporter plasmids (100 ng) were co-transfected into HEK293T cells with miR-1236 (1 μl) or off target control and 10 ng pRL-TK. Lipofectamine 2000 was used for transfection. Cells were collected for luciferase assay 48 h post transfection and were lysed with 100 ul 1/6 negative lysis buffer (Promega) for 15 min; Lysate (20 μl) was added with Luciferase Assay Buffer and mixed to measure firefly luciferase on a Veritas luminometer (Turner BioSystems, Sunnyvale, CA, USA). Then Stop & Glo Reagent (30 μl) was added and mixed to detect renilla luciferase.

Statistical analysis
Statistical analysis was performed using a paired t test with SigmaStat 2.0 (Systat Software, San Jose, CA, USA).

Acknowledgments
We gratefully thank Dr. Li Wu, Prof. Yong-Tang Zheng and Dr. Paul Zhou for the gifts of plasmids, antibodies or cell lines.

Author Contributions
Conceived and designed the experiments: JW EC SX. Performed the experiments: LM CS. Analyzed the data: LM CS JW. Contributed to the writing of the manuscript: JW EC.

References
1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
2. Mráz M, Pospíšilova S, Malinova K, Slapak I, Mayer J (2009) MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 50: 506–509.
3. He L, Thomson JM, Hemann MT, Hernandez-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828–833.
4. Swaminathan S, Xu Y, Rao S, et al. (2013) The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection. Eur J Immunol 43: 510–520.
12. Swaminathan G, Navas-Martin S, Martin-Garcia J (2014) MicroRNAs and HIV-1 infection: Antiviral Activities and Beyond. J Mol Biol 426: 1178–1197.
13. Van Lint C, Bouchat S, Marcello A (2013) HIV-1 transcription and latency: an update. Retrovirology 10: 67.
14. Detiska MG, Pasiris A, Paraskevis D (2012) MicroRNAs and HIV latency: a complex and promising relationship. AIDS Rev 14: 188–194.
15. Huang J, Wang F, Argyris E, Chen K, Liang Z, et al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13: 1241–1247.
16. Ahhawala JK, Khan SZ, Soni K, Rawat P, Gupta A, et al. (2008) Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 5: 117.
17. Nathans R, Chu CY, Serquina AK, Liu CC, Cao H, et al. (2009) Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell 34: 696–709.
18. Hanifman M, Scaria V, Filali B, Brahnamachi SK (2005) Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 337: 1214–1218.
19. Sun G, Li H, Wu X, Covaarribas M, Scherer L, et al. (2012) Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res 40: 2101–2106.
20. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, et al. (2011) Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 472: 495–498.
21. Kulkarni S, Qi Y, O’Huinigin C, Pererra F, Ramurun V, et al. (2013) Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci U S A 110: 20705–20710.
22. Chiang K, Liu H, Rice AP (2013) miR-132 enhances HIV-1 replication. Virology 430: 1–4.
23. Zhang HS, Wu TC, Sang WW, Ruan Z (2012) MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1. Biochim Biophys Acta 1823: 1017–1023.
24. Zhang HS, Chen YY, Wu TC, Sang WW, Ruan Z (2012) MiR-34a is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation through the SIRT1/NFkappaB pathway. FEBS Lett 580: 4203–4207.
25. Zhang Y, Fan M, Geng G, Liu B, Huang Z, et al. (2014) A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region. Retrovirology 11: 23.
26. Bergamaschi A, Pancino G (2010) Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7: 31.
27. Collini P, Noursadeghi M, Sabroe I, Miller RF, Dockrell DH (2010) Monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 184: 3236–3243.
28. Triques K, Stevenson M (2004) Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol 78: 5525–5527.
29. Dong C, Kwas C, Wu L (2009) Transcriptional restriction of human immunodeficiency virus type 1 gene expression in undifferentiated primary monocytes. J Virol 83: 5158–3527.
30. Arefi V, Riviere J, Jarrosson-Wuilleme L, Goujon C, Ragel D, et al. (2008) Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol 82: 6537–6563.
31. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, et al. (1996) Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol 70: 3863–3869.
32. Neil S, Martin F, Iedea Y, Collins M (2001) Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 75: 5448–5456.
33. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, et al. (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 178: 6381–6389.
34. Laguette N, Sobhian B, Casartelli N, Ringarde M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 653–657.
35. Hrecka K, Hao C, Gierszeewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 630–661.
36. Berger A, Somner AF, Zwang J, Hamdorf M, Wenzel K, et al. (2011) SAMHD1-deficient CD4+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog 7: e1002425.
37. Lahouassa H, Daddacha D, Holmnn H, Ayinde D, Logue EC, et al. (2012) SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 13: 223–228.
38. Siik JM, Clements JE, Witwer KV (2012) microRNA profiles of monocyte-lineage cells are consistent with complicated roles in HIV-1 restriction. Viruses 4: 1844–1864.
39. Sheng CJ, Jia YH, Tian RR, Ding M, Zhang C, et al. (2012) Translation of Pur-alpha is targeted by cellular miRNAs to modulate the differentiation-dependent susceptibility of monocytes to HIV-1 infection. Front Cell Infect Virol 2: 1–9.
40. Kisse Z, Houzet L, Jeang KT (2012) MicroRNAs and HIV-1: complex interactions. J Biol Chem 287: 40804–40890.
41. Sun TL, Rice AP (2009) miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS Pathog 5: e1000263.
42. Belzile JP, Dussit G, Rouagne N, Mercier J, Finzi A, et al. (2007) HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 3: e65.
43. Belzile JP, Richard J, Rouagne N, Xiao Y, Cohen EA (2010) HIV-1 Vpr induces the K4-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest. J Virol 84: 3320–3330.
44. Hrecka K, Gierszeewska M, Sevastava S, Kostakiewics L, Swanson SK, et al. (2007) Lentiviral Vpr uspsus T cells and SAMHD1 are the key intracellular host factors targeted by HIV-1 for viral replication. Cell Host Microbe 4: 495–504.
45. Konig R, Zhou Y, Elleder D, Diamond TL, Bonnay GM, et al. (2000) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135: 49–60.
46. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921–926.
47. Wang X, Singh S, Jung HY, Yang G, Jun S, et al. (2013) HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J Biol Chem 288: 15474–15480.
48. Kogan M, Deshmane S, Sawaya BF, Gracey EF, Khalili K, et al. (2013) Inhibition of NF-kappaB activity by HIV-1 Vpr is dependent on Vpr binding protein. J Cell Physiol 228; 781–790.
49. Gerard FC, Yang R, Romani B, Poisson A, Belzile JP, et al. (2014) Defining the Interactions and Role of DCAF1/VPRBP in the DDB1-Cullin4A E3 Ubiquitin Ligase Complex Engaged by HIV-1 Vpr to Induce a G2 Cell Cycle Arrest. PLoS One 9: e91915.
50. Laguette N, Riegard C, Huer P, Bassous J, Yatham A, et al. (2014) Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156: 134–145.
51. Ahn J, Yu T, Novince Z, Guerrero-Santoro J, Rapic-Otinu V, et al. (2010) HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for pro tease-dependent degradation. J Biol Chem 285: 37333–37341.
52. Ahn J, Hao C, Yang R, Delucia M, Meherens J, et al. (2012) HIV/Simian Immunodeficiency Virus (SIV) Accessory Virulence Factor Vpx Loads the Host Cell Restriction Factor SAMHD1 onto the E3 Ubiquitin Ligase Complex. Cell Chem Pathol 34: 12350–12358.
53. Qin Y, Li Y, Liu W, Tian R, Guo Q, et al. (2011) Penicillin marnelli-in stimulated dendritic cells enhance HIV-1 trans-infection and promote viral infection by activating primary CD4+ T cells. PLoS ONE 6: e27609.